Gut microbiota and their metabolites in cardiovascular disease

The gut microbiome affects the development and progress of various types of disease such as obesity, diabetes, atherosclerosis and arterial thrombosis. Gut microbiome derived metabolites have been established to be predictive of arterial thrombosis in epide-miological studies. In these studies atherosclerosis and pro-thrombotic effect cannot be distinguished but preclinical studies show gut derived metabolites can induce platelet hyperreactivity and increase thrombotic potential. Gut commensals can also in-fluence platelets through serotonin synthesis and may enhance Von Willebrand factor production. The effects on secondary hae-mostasis are less studied. In antiphospholipid syndrome, a thrombotic auto-immune disorder, autoreactive T cells and anti-bodies cross-react with auto-antigen mimicking peptides from gut commensals which appears to contribute to the pathophysiology. This review focusses on the prothrombotic effect of the gut microbiome and aims to provide insight into its influence on thromboembolic disease and the haemostatic system. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).

Automated summary

The gut microbiome can affect the development and progression of diseases such as obesity, diabetes, atherosclerosis, and arterial thrombosis. Gut microbiome-derived metabolites have been shown to predict arterial thrombosis, potentially influencing platelet function and Von Willebrand factor production. In certain autoimmune disorders, gut commensals may play a role in disease pathogenesis.